Valuation: RELH PHAR

Market Cap 13.29B 139M 122M 116M 104M 197M 199M 1.38B 532M 6.79B 520M 509M 21.77B P/E 2024
19.3x
P/E 2025 99.9x
Enterprise Value 13.21B 138M 121M 115M 104M 196M 198M 1.37B 529M 6.75B 517M 506M 21.64B EV / Sales 2024
4.59x
EV / Sales 2025 29x
Free-Float
10.68%
Yield 2024
1.22%
Yield 2025 0.05%
1 week+8.98%
Current month+39.64%
1 month+40.11%
3 months+116.02%
6 months+104.48%
Current year+4.71%
1 week 55.11
Extreme 55.11
63.39
1 month 44.26
Extreme 44.26
63.39
3 years 2.04
Extreme 2.0425
65.26
5 years 0.24
Extreme 0.24456215
65.26
Manager TitleAgeSince
Chief Executive Officer 53 2012-05-25
Director of Finance/CFO - 2024-07-09
Compliance Officer - 2026-06-14
Director TitleAgeSince
Director/Board Member 46 2012-05-22
Chairman 53 -
Director/Board Member 52 2023-08-11
Change 5-day change 1-year change 3-year change Capi.($)
+2.70%+8.98%+73.01%+1,495.88% 277M
-1.56%+1.71%+53.43%+117.47% 1,056B
-0.49%-0.90%+43.86%+71.93% 645B
-0.05%-0.64%+13.75%+77.66% 465B
-1.84%-0.78%+75.05%+43.27% 368B
-0.06%-3.88%+34.32%+40.74% 335B
-0.79%+2.01%+19.82%+28.48% 275B
-1.19%-1.21%+9.82%+12.15% 255B
-0.09%+4.37%+50.19%+59.16% 229B
-0.75%-0.56%+35.61%+103.14% 188B
Average -0.69%+0.12%+40.89%+204.99% 423.98B
Weighted average by Cap. -0.83%+0.30%+40.98%+73.47%

Financials

2024 2025
Net sales 765M 7.97M 7.02M 6.65M 6.01M 11.32M 11.47M 79.61M 30.64M 391M 29.95M 29.29M 1.25B 327M 3.41M 3.01M 2.85M 2.57M 4.85M 4.91M 34.08M 13.11M 167M 12.82M 12.54M 536M
Net income 185M 1.93M 1.7M 1.61M 1.46M 2.74M 2.78M 19.3M 7.43M 94.77M 7.26M 7.1M 304M 95.75M 999K 879K 833K 752K 1.42M 1.44M 9.97M 3.84M 48.95M 3.75M 3.67M 157M
Net Debt -68.26M -712K -627K -594K -536K -1.01M -1.02M -7.11M -2.74M -34.9M -2.67M -2.62M -112M -79.41M -828K -729K -691K -624K -1.18M -1.19M -8.27M -3.18M -40.6M -3.11M -3.04M -130M
Logo RELH PHAR
Shukra Pharmaceuticals Limited is an India-based pharmaceutical company engaged in developing, manufacturing and marketing a range of pharmaceutical products globally and domestically. The Company’s product portfolio consists of tablet and capsules (general) solid oral dosage form and small volume parenteral- liquid injection vial and ampules. The Company’s products include Losartan Potassium Tablets USP 50 mg, Glimepiride Tablets USP 2 mg, Pantoprazole Tablets USP 40 mg, Methocarbamol Tablets USP 500 mg, Omeprazole Capsule IP 20 mg, Amlodipine besylate Tablets USP 5 mg, Ranitidine Tablets USP 150 mg, Ranitidine Tablets USP 300 mg, Ciprofloxacin Tablets USP 250 mg, Ciprofloxacin Tablets USP 500 mg, Atorvastatin Tablets USP 10mg, Sildenafil citrate Tablets BP 100 mg, Diclofenac Sodium Tablets BP 50 mg, Mebendazole Tablets USP 100 mg, Paracetamol Tablets BP 500 mg, Artemether 80 mg and Lumefantrine 480 mg Tablets, Clotrimazole Vaginal Tablets 100 mg and others.
Employees
-
Date Price Change Volume
26-09-30 ₹62.04 +2.70% 771,798
26-09-29 ₹60.41 +1.70% 680,936
26-09-28 ₹59.40 +6.32% 796,063
26-09-25 ₹55.87 +0.25% 200,887
26-09-24 ₹55.73 -2.11% 282,024